DALLAS, Sept. 7, 2021 /PRNewswire/ -- Lantern
Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical
company using its proprietary RADR® artificial
intelligence ("A.I.") platform to transform the cost, pace, and
timeline of oncology drug discovery and development, today
announced it will be participating in two upcoming virtual investor
conferences.
Colliers Institutional Investor
Conference
Panna Sharma,
President & CEO of Lantern Pharma, will be hosting one-on-one
meetings at the 2021 Colliers Institutional investor conference
being held virtually September 9-10,
2021. Investors interested in arranging a meeting should
contact their Collier sales representative.
H.C. Wainwright 23rd Annual Global Investment
Conference
Mr. Sharma will be presenting at the H.C.
Wainwright 23rd Annual Global Investment Conference
being held virtually between September
13-15, 2021. Lantern's presentation will be available
on-demand to registered attendees via the conference platform
beginning Monday, September 13, 2021,
at 7:00 AM Eastern Time. The webcast
can be accessed here and on the investor relations section of
Lantern's website at https://ir.lanternpharma.com/. Management will
also be participating in one-on-one meetings with qualified members
of the investor community throughout the conference.
About Lantern Pharma
Lantern Pharma (LTRN) is a
clinical-stage oncology-focused biopharmaceutical company
leveraging its proprietary RADR® A.I. platform and
machine learning to discover biomarker signatures that identify
patients most likely to respond to its pipeline of genomically
targeted therapeutics. Lantern is currently developing four drug
candidates and an ADC program across eight disclosed tumor targets,
including two phase 2 programs. By targeting drugs to patients
whose genomic profile identifies them as having the highest
probability of benefiting from the drug, Lantern's approach
represents the potential to deliver best-in-class outcomes. More
information is available at: www.lanternpharma.com and Twitter
@lanternpharma.
CONTACTS:
Investor Relations
David
Waldman, Crescendo Communications, LLC
IR@lanternpharma.com
212-671-1021
Public Relations
Nicholas
Koulermos, Vice President – 5W Public Relations
lantern@5wpr.com
646-843-1812
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lantern-pharma-to-participate-in-two-upcoming-virtual-investor-conferences-during-september-301370269.html
SOURCE Lantern Pharma